Barclays Sticks to Its Buy Rating for Cardinal Health (CAH)

In a report released today, Glen Santangelo from Barclays maintained a Buy rating on Cardinal Health, with a price target of $258.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Santangelo covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical, Cardinal Health, and Cencora. According to TipRanks, Santangelo has an average return of 5.3% and a 52.85% success rate on recommended stocks.

In addition to Barclays, Cardinal Health also received a Buy from TD Cowen’s Charles Rhyee in a report issued on February 10. However, on the same day, J.P. Morgan maintained a Hold rating on Cardinal Health (NYSE: CAH).

Based on Cardinal Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $65.44 billion and a net profit of $471 million. In comparison, last year the company earned a revenue of $55.26 billion and had a net profit of $400 million

Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CAH in relation to earlier this year. Earlier this month, Aaron E Alt, the CFO of CAH sold 4,242.00 shares for a total of $947,556.06.